KR20090087971A - 광범위 스펙트럼의 항-바이러스 치료제 및 예방제 - Google Patents

광범위 스펙트럼의 항-바이러스 치료제 및 예방제 Download PDF

Info

Publication number
KR20090087971A
KR20090087971A KR1020097016110A KR20097016110A KR20090087971A KR 20090087971 A KR20090087971 A KR 20090087971A KR 1020097016110 A KR1020097016110 A KR 1020097016110A KR 20097016110 A KR20097016110 A KR 20097016110A KR 20090087971 A KR20090087971 A KR 20090087971A
Authority
KR
South Korea
Prior art keywords
domain
sialidase
virus
influenza
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020097016110A
Other languages
English (en)
Korean (ko)
Inventor
유 망
팡 팡
Original Assignee
유 망
팡 팡
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유 망, 팡 팡 filed Critical 유 망
Publication of KR20090087971A publication Critical patent/KR20090087971A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Nanotechnology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020097016110A 2002-11-22 2003-11-21 광범위 스펙트럼의 항-바이러스 치료제 및 예방제 Ceased KR20090087971A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42853502P 2002-11-22 2002-11-22
US60/428,535 2002-11-22
US46421703P 2003-04-19 2003-04-19
US60/464,217 2003-04-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020057009272A Division KR20050085130A (ko) 2002-11-22 2003-11-21 광범위 스펙트럼의 항-바이러스 치료제 및 예방제

Publications (1)

Publication Number Publication Date
KR20090087971A true KR20090087971A (ko) 2009-08-18

Family

ID=32397132

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020097016110A Ceased KR20090087971A (ko) 2002-11-22 2003-11-21 광범위 스펙트럼의 항-바이러스 치료제 및 예방제
KR1020057009272A Ceased KR20050085130A (ko) 2002-11-22 2003-11-21 광범위 스펙트럼의 항-바이러스 치료제 및 예방제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020057009272A Ceased KR20050085130A (ko) 2002-11-22 2003-11-21 광범위 스펙트럼의 항-바이러스 치료제 및 예방제

Country Status (8)

Country Link
US (2) US8084036B2 (https=)
EP (1) EP1567185B1 (https=)
JP (1) JP5348651B2 (https=)
KR (2) KR20090087971A (https=)
CN (2) CN101804200A (https=)
AU (1) AU2003294401C1 (https=)
CA (1) CA2506526C (https=)
WO (1) WO2004047735A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11238485B2 (en) 2015-01-19 2022-02-01 n-tuple.co.ltd Method and device for providing digital goods using URL coupon

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2506526C (en) * 2002-11-22 2017-04-18 Mang Yu Broad spectrum anti-viral therapeutics and prophylaxis
US7807174B2 (en) * 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
US8512710B2 (en) 2002-11-22 2013-08-20 Ansun Biopharma, Inc. Class of therapeutic protein based molecules
US8337814B2 (en) * 2005-12-15 2012-12-25 Topical Sinus Therapeutics, Inc. Treatment of active infections, sinusitis, rhinitis, and related neurological disorders and related compositions
CN101404980A (zh) 2006-01-24 2009-04-08 耐百生物制药有限公司 大分子微球的制备技术
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US8080645B2 (en) * 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8084443B2 (en) 2007-10-01 2011-12-27 Longhorn Vaccines & Diagnostics Llc Biological specimen collection and transport system and methods of use
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
MX2009007139A (es) 2006-12-28 2009-10-08 Centocor Ortho Biotech Inc Metodos y vectores para generar inmunoglobulinas no sialiladas.
CA2989778C (en) * 2007-01-19 2020-06-30 Kai Pharmaceuticals, Inc. Method of modifying peptide compositions
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
EP2772267B1 (en) 2007-08-27 2016-04-27 Longhorn Vaccines and Diagnostics, LLC Immunogenic compositions and methods
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
US8187591B2 (en) * 2007-10-11 2012-05-29 The Regents Of The University Of California Methods of treating coagulopathy
MX2011004840A (es) * 2008-11-07 2011-08-08 Anhydro Biolog Ltd Composiciones de vacuna.
JP2010229122A (ja) * 2009-03-06 2010-10-14 Kumamoto Univ 抗癌剤、医薬、及び癌疾患の検査薬
CN102448438A (zh) * 2009-03-26 2012-05-09 普马特里克斯公司 抗流行性感冒调配物及方法
JP2011037765A (ja) * 2009-08-11 2011-02-24 Kitasato Institute 新規ペプチド、並びにトリプシン阻害剤、抗インフルエンザウイルス剤、及び抗体
GB0916578D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
CN103200938B (zh) 2010-08-30 2018-07-31 普马特里克斯营业公司 干燥粉末配方及用于治疗肺部疾病的方法
WO2012030645A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
BR112013007304B1 (pt) 2010-09-29 2021-12-14 Pulmatrix, Inc. Pós secos de cátion de metal monovalente para inalação
PT3470057T (pt) 2010-09-29 2021-12-03 Pulmatrix Operating Co Inc Pós secos catiónicos compreendendo sais de magnésio
EP3494989B1 (en) 2012-01-26 2025-07-16 Longhorn Vaccines and Diagnostics, LLC Composite antigenic sequences and vaccines
WO2013123521A1 (en) 2012-02-17 2013-08-22 Nexbio, Inc. Methods, Compounds and Compositions for Treatment of Parainfluenza Virus in Immunocompromised Patients
CN107596518B (zh) 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
EP2866792A4 (en) 2012-06-28 2016-08-17 Ansun Biopharma Inc MICROPARTICLE FORMULATIONS FOR DELIVERY TO LOWER AND CENTRAL RESPIRATORY PATHS AND METHOD OF PREPARING THEM
AU2014248455B2 (en) 2013-04-01 2018-12-06 Pulmatrix Operating Company, Inc. Tiotropium dry powders
US10300116B2 (en) 2013-06-10 2019-05-28 Ansun Biopharma, Inc. Treatment for BK polyomavirus infection
WO2015184356A1 (en) 2014-05-30 2015-12-03 Ansun Biopharma, Inc. Treatment of middle east respiratory syndrome coronavirus
WO2016044656A1 (en) 2014-09-17 2016-03-24 Ansun Biopharma, Inc. Treatment of infection by human enterovirus d68
WO2016115616A1 (en) * 2015-01-21 2016-07-28 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Inhibition of cellular proteases as treatment for influenza
EP3294448A4 (en) 2015-05-14 2018-12-12 Longhorn Vaccines and Diagnostics, LLC Rapid methods for the extraction of nucleic acids from biological samples
US20180271997A1 (en) * 2016-05-31 2018-09-27 Tianxin Wang Methods and Reagents to Treat Tumor and Cancer
CN109641038A (zh) 2016-07-01 2019-04-16 小利兰·斯坦福大学理事会 靶向细胞表面编辑的共轭物
US20200085849A1 (en) * 2017-05-18 2020-03-19 Elysium Health, Inc. Methods and compositions for improving sleep
EP3735458A4 (en) 2018-01-03 2022-04-27 Palleon Pharmaceuticals Inc. RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF
GB201814905D0 (en) * 2018-09-13 2018-10-31 Herwald Heiko Treatment
CN114269937B (zh) * 2019-07-03 2026-04-24 帕利昂制药有限公司 重组唾液酸酶及其使用方法
CA3148394A1 (en) * 2019-07-23 2021-01-28 Csts Health Care Inc. Platelet-facilitated delivery of therapeutic compounds
US12485166B2 (en) 2020-02-06 2025-12-02 Longhorn Vaccines And Diagnostics, Llc Vaccines for the treatment and prevention of zoonotic infections
IE20210235A1 (en) 2020-10-20 2023-08-16 Longhorn Vaccines & Diagnostics Llc Immunogenic antigens

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3439089A (en) * 1968-03-27 1969-04-15 Merck & Co Inc Medicated hard candy
US5643758A (en) * 1987-03-10 1997-07-01 New England Biolabs, Inc. Production and purification of a protein fused to a binding protein
RU2054180C1 (ru) 1991-08-21 1996-02-10 Жирнов Олег Петрович (н/п) Способ лечения вирусных респираторных инфекций
US5376633A (en) * 1992-09-30 1994-12-27 Lezdey; John Method for deactivating viruses in blood component containers
US5985859A (en) * 1994-04-14 1999-11-16 The University Of Alabama Methods of inhibiting bacterial sialidase
WO1998031817A2 (en) * 1997-01-14 1998-07-23 Hopital Sainte-Justine Human lysosomal sialidase and therapeutic uses thereof
US6251392B1 (en) * 1997-10-20 2001-06-26 Epicyte Pharmaceuticals, Inc. Epithelial cell targeting agent
ES2246093T3 (es) * 1998-10-16 2006-02-01 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Patogenicida molecular que induce una resistencia a la enfermedad en las plantas.
US6855801B1 (en) * 1999-02-02 2005-02-15 Thomas Jefferson University Peptides modulating activities of heparin other glycosaminoglycans or proteoglycans
US6737511B1 (en) * 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
US20020025320A1 (en) * 1999-08-20 2002-02-28 Prosper Boyaka Sialidases as mucosal adjuvants
CA2506526C (en) * 2002-11-22 2017-04-18 Mang Yu Broad spectrum anti-viral therapeutics and prophylaxis
US7807174B2 (en) * 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
CN101404980A (zh) * 2006-01-24 2009-04-08 耐百生物制药有限公司 大分子微球的制备技术

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11238485B2 (en) 2015-01-19 2022-02-01 n-tuple.co.ltd Method and device for providing digital goods using URL coupon

Also Published As

Publication number Publication date
US8084036B2 (en) 2011-12-27
JP5348651B2 (ja) 2013-11-20
AU2003294401A1 (en) 2004-06-18
CN1729013B (zh) 2012-10-03
AU2003294401C1 (en) 2008-09-18
CN101804200A (zh) 2010-08-18
WO2004047735A3 (en) 2004-09-23
JP2006508193A (ja) 2006-03-09
EP1567185B1 (en) 2020-02-19
EP1567185A2 (en) 2005-08-31
CA2506526C (en) 2017-04-18
KR20050085130A (ko) 2005-08-29
EP1567185A4 (en) 2009-04-22
CN1729013A (zh) 2006-02-01
HK1080763A1 (en) 2006-05-04
US20080075708A1 (en) 2008-03-27
AU2003294401B2 (en) 2007-11-29
WO2004047735A2 (en) 2004-06-10
CA2506526A1 (en) 2004-06-10
US20050004020A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
AU2003294401C1 (en) Broad spectrum anti-viral therapeutics and prophylaxis
AU2005285461B2 (en) A novel class of therapeutic protein based molecules
US20160184407A1 (en) Novel Class of Therapeutic Protein Based Molecules
AU2008200954B2 (en) Broad spectrum anti-viral therapeutics and prophylaxis
HK1080763B (en) Broad spectrum anti-viral compounds, pharmaceutical formulations and the use thereof
HK1246351B (en) A novel class of therapeutic protein based molecules
HK1224329B (en) A novel class of therapeutic protein based molecules
HK1246351A1 (en) A novel class of therapeutic protein based molecules
HK1201562B (en) A novel class of therapeutic protein based molecules
HK1128935A (en) A novel class of therapeutic protein based molecules
HK1128935B (en) A novel class of therapeutic protein based molecules

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20090730

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20090826

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20090901

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20100302

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20090901

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I